Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +1.50p +2.94% 52.50p 52.00p 53.00p 57.00p 50.50p 51.00p 571,807 16:08:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 0.6 -8.9 -10.1 - 75.33

Angle Share Discussion Threads

Showing 48676 to 48697 of 48700 messages
Chat Pages: 1948  1947  1946  1945  1944  1943  1942  1941  1940  1939  1938  1937  Older
DateSubjectAuthorDiscuss
16/1/2019
02:42
It's worth examining that Edison figure for ovarian cancer. As of 2015, they projected peak sales of $25.4m in 2030 based on 20% market share and revenue of roughly $300 per test. There are roughly 200,000 ovarian masses going to surgery every year in the US and the same in Europe. 400,000*0.2*$300 = $24m so about right. I think this is a conservative model. It assumes Parsortix slide sales only, whereas the proposed test now includes a Ziplex chip and some kind of proprietary algorithm, plus a price below the $336 Vermillion gets for an OVA1 test that barely works. In reality, sales will either be next-to-nothing (like Vermillion), or else it will be a valuable product. What is this one application worth? Well, Vermillion has a market cap of $51m for a product that seems hopeless.
mirako
16/1/2019
00:42
Edison have previously estimated peak breast cancer sales of $75m / year and to only reach that level 9 years after launch. Not large sums being talked about then. Indeed not even 1/10th of a blockbuster. Ovarian is even smaller, with peak sales forecast of just $24m / year. And how much dilution before then? In the 2014 Annual Report the shares in issue were just 45,129,800 and the options potentially exercisable were 4,346,000. By the end of 2018, the shares in issue were 143,486,522 and the options potentially exercisable were 20,555,806. This is a massive amount of dilution. How much more to come? Alternatively, if they partner, ANGLE will get only a minor fraction of the above income. I then flag up the already reached current market cap of $96m. A lot of sales are needed to justify that market cap at this stage, given the risk of failure and the likely dilution. Overvalued or not I ask?
sicilian_kan
15/1/2019
23:45
Re: Cellsearch vs others Dictionary definition. "When you enumerate a list of things, you name each one in turn." "If you harvest a large number of things, you collect them, often by making great efforts."
hashertu
15/1/2019
23:22
To bed, buywell3, sorry I mean cot.
thailand
15/1/2019
23:17
I guess what I am saying is that the market for CTC related products/services is now IMO not as big or as lucrative as J&J once thought The types of cancers that can use CTC technology are fewer than many thought The cancers that can use it have sufferers that can opt for earlier preventative surgery if genetic testing indicates a disposition or the cancer is detected in early stage That is why J&J offloaded CellSearch .... a very limited market opportunity
buywell3
15/1/2019
23:06
CTC's are being talked about with connections to Breast Cancer and Prostrate Cancer From personal experience I can honestly state the following 3 family members , one close and two extended developed breast cancer ( genetics via certain gene mutations make many women and family members disposed to this disease.) A decent consultant runs through the various options for treatment My close family member had a breast removed .... and lived another 19 years to a ripe old age . The two others didn't one had kemo ... one was into homeopathy and went that route Both died within 2 years . Many people that can afford it have breast removals after having a test to see that they have the bad gene hTTps://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet Many men that can afford it have their prostrate removed , the same two bad genes are involved hTTps://www.livescience.com/51180-preventive-removal-of-prostate-makes-sense-for-some-patients.html Thus surgical removal for such cancers presents the only cure
buywell3
15/1/2019
22:30
CTCs in your opinion is flawed.What qualifications do you have to come to that conclusion. Clown. Donkey. ee aw.
ih_575893
15/1/2019
22:23
If you are not short, both of you, why bring up spurious ' detail ' that you well know isn't really an issue. Is it just ego? Seen it before. Increasingly on bbs. Happy to look at the negatives, but your retorts are getting more red herring with the telling
waterloo01
15/1/2019
22:22
Something for kindergarten in the morning.
thailand
15/1/2019
22:20
Buywell, Parsortix operates independently of cell surface markers and captures all CTC's whether EpCAM positive or negative and so does not suffer form the limitations of CellSearch regarding which cells can be captured. PLEASE PLEASE do some research into Parsortix before continuing to waste everybody's time including your own - you may be pleasantly surprised.
miavoce
15/1/2019
22:17
We're all well aware that FDA approval is needed, but the point is the critical trial is taking place now and due to finish this year AIUI. If that's a success then this could prove to be worth a multiple of the current price and if it's not then I for one will just accept it and take back whatever I can from my investment. It's all about risk and reward, the risk is high but the rewards could simlarly be high. Does it not occur to you that many of us understand that?
arthur_lame_stocks
15/1/2019
22:01
The use of CTC's was bought into question in this article ... CellSearch was used Promise and Limits of the CellSearch® Platform for Evaluating Pharmacodynamics in Circulating Tumor Cells (CTC) hTTps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074690/ Published online 2016 Jun 15 Abstract Circulating tumor cells (CTCs), defined by capture from blood with anti-EpCAM antibodies, have established prognostic value in specific epithelial cancers, but less is known about their utility for assessing patient response to molecularly targeted agents via measurement of pharmacodynamic (PD) endpoints. We discuss the use of CellSearch CTC isolation technology for monitoring PD response in early phase trials. We present representative data from three clinical trials with the PARP inhibitor veliparib (ABT-888) suggesting that CTCs can be used to measure PD effects, but our experience points to the difficulty in obtaining sufficient EpCAM-expressing CTCs from patients with advanced disease to reach statistically significant conclusions about PD effects from each trial, instead often leading to hypothesis generating information. Overall, the level of phenotypic heterogeneity observed in specimens from patients with advanced carcinomas suggests caution in the use of cell-surface differentiation marker-based methods for isolating CTCs. Conclusions The application of the CellSearch technology in monitoring drug responses in patients with advanced cancers within the NCI clinical trials network has yielded several key insights including demonstrating that patients with a variety of advanced stage carcinomas have low numbers of EpCAM-defined CTCs, independent of disease type or participating clinical site. This was a major limiting factor in our efforts to statistically quantitate CTCs and CTC-associated biomarkers. It also serves as a caution for the use of individual cell-surface differentiation markers to isolate and characterize CTCs from patients with advanced carcinomas, as there could well be additional populations of important but currently unidentified circulating cells to be discovered and categorized. This is a double-edged sword, providing an exciting area of future research as well as cautioning scientists and clinicians about the extent and validity of CTC results reported from advanced-stage patients.
buywell3
15/1/2019
21:43
Why does the ownership of a barely useful product have any bearing on the discussion ?
miavoce
15/1/2019
21:42
Try looking at the agenda for this years Molecular Med Trial-Con and you will get a sense of how liquid biopsy and utilising of CTC's is rapidly maturing.
miavoce
15/1/2019
21:42
You do agree though that J&J owned CellSearch don't you ? via Janssen eg Johnson & Johnson Announces Completion of Acquisition ... - Janssen hTTps://www.janssen.com/johnson-johnson-announces-completion-of-acquisition-of-ac... Jun 16, 2017 - The acquisition was completed through an all-cash public tender offer by Johnson & Johnson's Swiss subsidiary, Janssen Holding GmbH
buywell3
15/1/2019
21:41
Buywell3, get to bed or you'll be late for school in the morning.
thailand
15/1/2019
21:40
The future research mentioned in the conclusion has now happened and liquid biopsy is a reality Buywell - please catch up with events.
miavoce
15/1/2019
21:39
Cellsearch was never going to make a load of dosh and never will because, as I've tried to explain to you Buywell, it can't harvest CTC's and therefore is pretty useless when compared to Parsortix. Since 2013, when the paper you post was published, the prospect of liquid biopsy has become a reality and Parsortix is at the heart of this. This market is expected to be work $10-20 billion annum in years to come and Angle will get a slice of this. What is you agenda here Buywell, it clearly isn't to have an informed discussion ?
miavoce
15/1/2019
21:38
CTC's is IMO a flawed area which is why J&J got rid of CellSearch Circulating tumor cells (CTCs) have been reported to be a relevant prognostic biomarker in metastatic patients. However, their clinical use and impact is still under debate. We have thus comparatively and kinetically assessed two CTC detection methods according to the patient’s clinical follow up. Methods CTC counting and characterization were repeatedly performed during follow up in a patient with metastatic undifferentiated non-small cell lung cancer by using cytokeratin (CK)-dependent immunomagnetic separation (Miltenyi) and CK-independent, size-based isolation [isolation by size of tumor cells (ISET)] (Rarecells). Results Comparison between the two methods showed a parallel increase of CTC detected by ISET and worsening of the clinical status, while CK-dependent CTC numbers were decreasing, misleadingly suggesting a response to treatment. ISET results were in agreement with the clinical follow up showing Circulating tumor microemboli (CTM) and CTC expressing a mesenchymal marker with absence of epithelial markers. Conclusions This case report study shows the interest of a comparative and kinetic analysis of different methods for CTCs detection combined with their evaluation according to the clinical follow up. Our results should open up an area for future research and validation in larger clinical cohorts. hTTps://www.janssen.com/precision-medicine-janssen-diagnostics/about
buywell3
15/1/2019
21:31
And while I am at it, please provide supporting research that is independent. Thanks
l0ngterm
15/1/2019
21:30
The association of CTC clusters with metastasis is well established. The link below is interesting, it mentions methods of detecting and isolating CTCs and CTC clusters but Parsortix doesn't get a mention. However it does say at the end that a gold standard method to detect and isolate the clusters is needed to move the field forward - Could Parsortix be that method? https://www.researchgate.net/publication/311899400_CTC_clusters_in_cancer_progression_and_metastasis
davemac3
15/1/2019
21:29
Before I read this, please confirm When was the study published, by whom and how were the researchers funded, and by whom.
l0ngterm
Chat Pages: 1948  1947  1946  1945  1944  1943  1942  1941  1940  1939  1938  1937  Older
Your Recent History
LSE
AGL
Angle
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190116 05:52:40